AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
AbbVie presented new Phase 3 AFFIRM data at ACG 2026 showing subcutaneous SKYRIZI achieved higher endoscopic remission and ulcer-free endoscopy rates than placebo in moderately to severely active Crohn's disease. At week 24, 35.8% of overall patients achieved endoscopic remission, rising to 45.1% in advanced therapy-naïve patients, with 49.0% achieving ulcer-free endoscopy in that subgroup.
Key figures
- Drug Name
- SKYRIZI (risankizumab-rzaa)
- Phase Of Trial
- Phase 3
- Patients randomized
- 289
- Week24 ulcer free at naive
- 49.0%
- Week24 endoscopic remission overall
- 35.8%
- Week24 endoscopic remission at naive
- 45.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.